Northpointe Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Northpointe Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-33,075	Closed	-$474K	–	256
2014 Q4	$474K	Buy	+33,075	New	+$391K	0.06%	229

Other funds holding VNDA

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northpointe Capital's VNDA Position: Q1 2015 in Review

Northpointe Capital sold out of Vanda Pharmaceuticals (VNDA) in Q1 2015, closing a stake of 33,075 shares — an estimated $474K sold.

Northpointe Capital first reported a position in VNDA in Q4 2014 and held it in 1 quarter. The position peaked at $474K in Q4 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q1 2015.

Northpointe Capital reported no remaining Vanda Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Northpointe Capital sold 33,075 Vanda Pharmaceuticals shares in Q1 2015, an estimated $474K.
Northpointe Capital first reported a position in Vanda Pharmaceuticals in Q4 2014 and held it in 1 quarter.
Northpointe Capital's Vanda Pharmaceuticals position peaked at $474K in Q4 2014.
110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2015.

Based on Northpointe Capital's 13F filing for Q1 2015, filed 29 Apr 2015.